Compare HUBC & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HUBC | RDHL |
|---|---|---|
| Founded | 2017 | 2009 |
| Country | Israel | Israel |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6M | 3.3M |
| IPO Year | 2022 | 2012 |
| Metric | HUBC | RDHL |
|---|---|---|
| Price | $1.01 | $0.48 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 235.1K | 209.2K |
| Earning Date | 11-11-2026 | 09-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $17,592.31 |
| Revenue Next Year | N/A | $25.89 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.06 | $0.48 |
| 52 Week High | $8.68 | $2.26 |
| Indicator | HUBC | RDHL |
|---|---|---|
| Relative Strength Index (RSI) | 42.44 | 34.08 |
| Support Level | $0.27 | N/A |
| Resistance Level | $2.96 | $1.07 |
| Average True Range (ATR) | 0.86 | 0.03 |
| MACD | -0.45 | -0.01 |
| Stochastic Oscillator | 2.02 | 12.97 |
Hub Cyber Security Ltd is engaged in developing reliable quality assurance systems that support process and product enhancement and also operates in the industry of secured data fabric. The company serves various organizations and institutions operating in the security, electronics, aviation, telecommunications, and banking. The company has two operating segments: Product and Technology Segment and Professional Services Segment. The majority of revenue comes from the professional services segment, which provides data and cybersecurity and system security and reliability solutions and related services such as consulting, planning, integrating and ongoing servicing of cybersecurity, risk management, reliability and security projects and fully managed corporate cybersecurity services.
RedHill Biopharma Ltd is a specialty biopharmaceutical company mainly focused on the U.S. development and commercialization of drugs for GI diseases, infectious diseases, and oncology. The Company is mainly focused on the advancement of its development pipeline of clinical-stage therapeutic candidates and also commercializes its GI-related product, Talicia (omeprazole, amoxicillin, and rifabutin) in the U.S. Its therapeutic candidates include opaganib, RHB-204, RHB-104, RHB-102 (Bekinda), and RHB-107.